Form 4: Phio Pharmaceuticals Corp. Executive Acquires Shares Through Restricted Stock Unit Vesting

Robert J. Bitterman, Chairman, President, and CEO of Phio Pharmaceuticals Corp., acquired 15,500 shares of common stock through the vesting of a restricted stock unit on September 11, 2024.

Summary

• On September 11, 2024, Robert J. Bitterman, Chairman, President, and CEO of Phio Pharmaceuticals Corp., acquired 15,500 shares of common stock.
• This acquisition was due to the vesting of a restricted stock unit.
• The shares will vest in one year on the first anniversary.
• Following the transaction, Bitterman directly owns 17,832 shares of Phio Pharmaceuticals Corp.
• Robert M. Infarinato, Attorney-in-Fact, signed the Form 4 on September 13, 2024, on behalf of Robert J. Bitterman.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of an insider transaction related to executive compensation. The acquisition of shares by the CEO could be interpreted slightly positively, but it's not a major event.

Positives

• The acquisition of shares by the CEO could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency regarding the ownership of company stock by its executives.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates the CEO's confidence in the company.

Key Dates

Keywords

Form 4, Beneficial Ownership, Robert J. Bitterman, Phio Pharmaceuticals Corp., PHIO, Restricted Stock Unit, Share Acquisition, Insider Transaction